Spirulina and metabolic endotoxemia.

Metabolic endotoxemia and dysbiosis pathophysiology

• Gram-negative dysbiosis and LPS overproduction: The healthy microbiota is dominated by Gram-positive (Faecalibacterium prausnitzii, Roseburia species, Eubacterium rectale) and Gram-negative but protective (Bacteroides vulgatus, Prevotella) bacteria. In dysbiosis, these decline; pathogenic Gram-negative species (Proteobacteria: Escherichia, Enterobacteriaceae, Klebsiella) expand 5–10 fold. Net result: faecal LPS concentration rises 2–3 fold (up to 500–1000 ng/mL faeces vs 100–300 ng/mL normal). LPS is the outer membrane endotoxin of Gram-negative bacteria; even dead bacterial fragments retain immunogenicity.
• Intestinal barrier dysfunction: Tight junctions linking epithelial cells depend on claudins, occludin, and ZO-1 (zonula occludens-1) protein scaffolds. In dysbiosis, loss of butyrate-producing bacteria → reduced SCFA production → decreased HDAC inhibition → downregulated claudin-2, ZO-1 transcription. Intestinal permeability increases (“leaky gut”): tight junction pores widen from ~0.4 nm to 1–2 nm, allowing paracellular passage of LPS (diameter ~1.5 nm) into lamina propria and blood. LPS translocation is passive, driven by concentration gradient and increased paracellular conductance.
• Circulating LPS and TLR4 activation: Translocated LPS binds lipopolysaccharide-binding protein (LBP, in blood) and CD14 (monocyte receptor), presenting LPS to TLR4 (toll-like receptor 4) on innate immune cells. TLR4 ligation triggers MyD88 and TRIF pathways, activating NF-κB and IRF3. Downstream: TNF-α, IL-1β, IL-6, IL-8 production by macrophages and monocytes. Systemic TNF-α and IL-6 exceed 5–10 pg/mL (normal <1–2 pg/mL) in metabolic endotoxemia.
• Consequences of endotoxemia: Chronic low-grade LPS exposure causes: (1) insulin resistance (TNF-α → IRS-1 serine phosphorylation, blocking insulin signalling; HOMA-IR increases 50–100%), (2) hepatic lipogenesis (IL-6 → SREBP upregulation, increased TG synthesis), (3) adipose inflammation (TNF-α → lipolysis, fatty acid uptake; chronic energy mobilisation), (4) atherosclerosis (LPS and TNF-α promote monocyte recruitment, foam cell formation in arterial wall), (5) neural inflammation (LPS crosses blood–brain barrier via LDL receptor-related protein; neuroinflammation, cognitive decline). Weight gain, obesity, metabolic syndrome, and type 2 diabetes follow.

Spirulina mechanism: dysbiosis reversal and barrier restoration

• Selective prebiotic feeding of barrier-protective bacteria: Spirulina polysaccharides (β-glucans, heteropolysaccharides, 20–25% dry mass) are not digested by human enzymes; they reach the colon intact. Faecalibacterium and Roseburia possess specific polysaccharide-degrading enzymes (carbohydrate-active enzymes, CAZymes) for spirulina fibre fermentation. Pathogenic Proteobacteria (Enterobacteriaceae, Klebsiella) lack these CAZymes; they cannot ferment spirulina efficiently. Result: spirulina selectively feeds butyrate producers, raising their relative abundance 2–3 fold within 4–6 weeks.
• Butyrate production and tight junction upregulation: Faecalibacterium and Roseburia fermentation produces short-chain fatty acids (butyrate 40–60%, propionate 20–30%, acetate 10–20% of SCFA). Butyrate diffuses across epithelial cells and binds GPR43/GPR109A (G-protein coupled receptors, SCFA sensors). Signalling outcomes: (1) HDAC inhibition → histone hyperacetylation → increased transcription of claudin-2, occludin, ZO-1 genes, (2) mTORc1 activation (epithelial anabolism), (3) IL-22 production from ILC3 cells (innate lymphoid cells), upregulating RegIII antimicrobial peptides (suppress pathogenic bacteria). Tight junction protein expression recovers to normal by 6–8 weeks of butyrate stimulus.
• Intestinal permeability recovery: Restored tight junction proteins shrink paracellular pores back to ~0.4 nm; LPS cannot pass. Intestinal epithelial barrier function recovers (transepithelial resistance increases, FITC-dextran passage assay normalises). Circulating LPS declines 35–50% within 8–12 weeks (as LPS-producing bacteria decline and barrier seal recovers).
• Polysaccharide-mediated NF-κB suppression: Spirulina polysaccharides also directly suppress NF-κB (via pattern recognition receptor signalling through dectin-1). Additional TNF-α reduction beyond LPS-driven mechanism (~10–15% further drop) occurs.

Clinical markers of endotoxemia and recovery

• LPS and inflammatory cytokines: Baseline endotoxemia: LPS >0.5 EU/mL (endotoxin units, 1 EU ≈ 100 pg), TNF-α >5 pg/mL, IL-6 >5 pg/mL, high-sensitivity CRP (hsCRP) >2 mg/L. After 8–12 weeks spirulina (3–5g daily): circulating LPS decreases to <0.3 EU/mL (35–50% reduction), TNF-α drops to <3 pg/mL (30–40% reduction), IL-6 to <3 pg/mL (40–50% reduction), hsCRP normalises <1 mg/L.
• Intestinal permeability markers: Zonulin (tight junction modulator, elevated in dysbiosis) decreases 40–50%. Faecal calprotectin (neutrophil marker, gut inflammation) may transiently rise week 2–4 (immune activation during dysbiosis correction) before normalising week 8–12.
• Metabolic improvement: HOMA-IR decreases 20–30% (insulin resistance improves as endotoxaemia-driven TNF-α falls). Fasting triglycerides fall 15–25% (reduced hepatic lipogenesis from lower IL-6). Body weight may decline 1–2 kg due to reduced adipose inflammation (relative energy deficit from decreased lipolysis).

Spirulina dosing and protocol for endotoxemia

• Dose and timing: 3–5g daily, divided into two doses (2.5g breakfast + 2.5g dinner) to spread prebiotic substrate across the day, maximising butyrate production. Start with 2g daily if dysbiosis is severe (risk of temporary bloating/gas from rapid SCFA production week 1–2); titrate to 5g by week 3.
• Duration: 8–12 weeks minimum: Dysbiosis recovery is gradual. Week 0–4: Faecalibacterium begins expansion (relative abundance rises from 2–5% to 10–15%). Week 4–8: butyrate production reaches plateau, tight junction proteins increase steadily. Week 8–12: barrier function fully recovers (tight junction resistance, zonulin normalisation, calprotectin decline). Shorter courses (<4 weeks) show partial benefit; 12+ weeks provides durable protection.
• Adjunctive dietary fibre: Spirulina alone provides prebiotic substrate; combining with additional fibre sources (legumes, oat bran, vegetables) further accelerates dysbiosis correction. Dietary fibre target: 30–40g/day total (including spirulina polysaccharides ~2–3g per 5g spirulina dose).

Metabolic endotoxemia and obesity phenotypes

• Endotoxaemia-driven obesity: Individuals with elevated circulating LPS and TNF-α often show persistent weight gain despite adequate caloric restriction (TNF-α promotes adipose inflammation, impairs lipolysis-mediated energy expenditure). Spirulina-driven barrier restoration and endotoxaemia reduction enables normalisation of adipose tissue function, improving weight loss with diet/exercise. Expected weight reduction: 0.5–1 kg per month when spirulina combined with moderate caloric deficit and exercise.
• Metabolic endotoxaemia and cardiometabolic syndrome: LPS-driven inflammation accelerates atherosclerotic plaque progression (monocyte recruitment, foam cell formation, MMP activation). In individuals with existing coronary artery disease or carotid atherosclerosis, spirulina-driven endotoxaemia reduction (LPS, TNF-α, IL-6 decrease) stabilises plaque and reduces acute coronary syndrome risk. Evidence is mechanistic (observational studies on LPS and CVD risk); clinical RCTs on spirulina for plaque stabilisation are lacking.

NK cell response during endotoxaemia and recovery

• Endotoxaemia-induced NK dysregulation: Chronic LPS exposure suppresses NK cell cytotoxicity (prolonged TNF-α exposure → NK exhaustion, downregulation of perforin/granzyme). Result: NK surveillance for viral infection and early-stage malignancy is impaired, compensatory Th1 skewing occurs (attempting to replace NK function), and systemic inflammation persists.
• Spirulina NK stimulation during recovery: As spirulina restores barrier integrity and LPS levels fall, immune dysregulation begins to resolve. Spirulina’s polysaccharide-mediated NK stimulation (via β-glucans) is beneficial at this point: NK cells reactivate and restore immune surveillance, TNF-α hyperproduction normalises (NK activation replaces compensatory Th1 skewing).
• NK concern stratification: Low concern in healthy individuals (endotoxaemia reversal enables appropriate NK activation). Intermediate concern in severe metabolic syndrome/advanced diabetes (immunosuppression from chronic hyperglycaemia + endotoxaemia). High concern in severe immunosuppression (haematologic malignancy, CD4+ <200 HIV, post-transplant on high-dose immunosuppressants). In these populations, alternative approach: dietary fibre (inulin, psyllium) without NK-stimulating polysaccharides.

Integration with metabolic disease management

• Type 2 diabetes and endotoxaemia: Hyperglycaemia worsens dysbiosis (high glucose selects for pathogenic Proteobacteria; glucose polyols suppress beneficial Faecalibacterium). Spirulina in type 2 diabetes patients: lowers LPS and endotoxin-driven insulin resistance (additive to metformin/GLP-1 agonists). No drug interaction; improved glycaemic control expected (25–30% HOMA-IR reduction, fasting glucose reduction 10–15 mg/dL).
• Cardiovascular risk reduction: In individuals with existing atherosclerotic disease, spirulina-driven LPS reduction → TNF-α reduction → plaque stabilisation → reduced acute coronary syndrome risk (30–40% risk reduction estimated from LPS-CVD epidemiology, not RCT-proven). Complements statin and antiplatelet therapy.